← Leaderboards
David M Rekosh
University Of Virginia
$6,031,711
Attributed
$8,439,636
Total exposure
10
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $726K · FY2005–23$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$8,439,636 · 10
By mechanism
R01$5,791,231 · 4
R21$2,648,405 · 6
Top collaborators
- Marie-Louise Hammarskjold16 shared
Most similar at University Of Virginia
Same institution · by research overlap
- Marie-Louise Hammarskjold$8,275,607
- Patrick Evan Hager Jackson$1,452,000
Others in their field
Top investigators on “Virus”
- David Heimbrook · Leidos Biomedical Research, Inc.$512,873,478
- Lawrence Corey · Fred Hutchinson Cancer Center$392,679,667
- Barton F Haynes · Duke University$328,711,626
- Dennis R. Burton · Scripps Research Institute$276,624,892
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$274,342,142
- Richard Webby · St. Jude Children'S Research Hospital$265,067,789
Research focus
VirusElementsCellsPlayBaseMessenger RnaProteinsHiv InfectionsDesignStructureAffectRev GenesGene ExpressionMediatingBindingVariantLaboratoriesExperimental StudyAlternative SplicingInfectionEndogenous RetrovirusesPublicationsGenesComplex
Grant awards (29)
Host Factors That Restrict HIV mRNA With Retained Introns$161,500
R21 · FY2023 · AI
Effects of HIV Rev on Host Cell Gene Expression$161,500
R21 · FY2023 · AI · contact PI
Effects of HIV Rev on Host Cell Gene Expression$282,625
R21 · FY2022 · AI · contact PI
Host Factors That Restrict HIV mRNA With Retained Introns$282,625
R21 · FY2022 · AI
HIV, HERV-K and Human Cancer$403,750
R01 · FY2021 · CA
HIV, HERV-K and Human Cancer$403,750
R01 · FY2020 · CA
HIV, HERV-K and Human Cancer$509,230
R01 · FY2019 · CA
HIV, HERV-K and Human Cancer$524,710
R01 · FY2018 · CA
Role of HIV Rev in Reactivation from Latency$201,250
R21 · FY2018 · AI · contact PI
HIV, HERV-K and Human Cancer$401,250
R01 · FY2017 · CA
Role of HIV Rev in Reactivation from Latency$241,500
R21 · FY2017 · AI · contact PI
Functional Variation of Rev and RRE Activity During HIV Infection$298,040
R01 · FY2016 · GM
Functional Variation of Rev and RRE Activity During HIV Infection$298,040
R01 · FY2015 · GM
Functional Variation of Rev and RRE Activity During HIV Infection$298,040
R01 · FY2014 · GM
Functional Variation of Rev and RRE Activity During HIV Infection$50,000
R01 · FY2014 · GM
Functional Variation of Rev and RRE Activity During HIV Infection$298,040
R01 · FY2013 · GM
HIV Rev/RRE Variation and Constraints$188,217
R21 · FY2011 · AI · contact PI
HIV Rev/RRE Variation and Constraints$228,688
R21 · FY2010 · AI · contact PI
Compounds That Inhibit HIV Rev Function$406,514
R01 · FY2008 · AI · contact PI
Compounds That Inhibit HIV Rev Function$414,397
R01 · FY2007 · AI · contact PI
Compounds That Inhibit HIV Rev Function$440,468
R01 · FY2006 · AI · contact PI
Nef Localization Complex Formation and Function$228,500
R21 · FY2005 · AI
Nef Localization Complex Formation and Function$228,000
R21 · FY2004 · AI
HIV PARTICLE FORMATION AND RNA PACKAGING$257,650
R01 · FY2003 · AI
HIV Rev as a Therapeutic Target$222,000
R21 · FY2003 · AI
HIV PARTICLE FORMATION AND RNA PACKAGING$257,702
R01 · FY2002 · AI
HIV Rev as a Therapeutic Target$222,000
R21 · FY2002 · AI
HIV PARTICLE FORMATION AND RNA PACKAGING$255,642
R01 · FY2001 · AI
HIV PARTICLE FORMATION AND RNA PACKAGING$274,008
R01 · FY2000 · AI